论文部分内容阅读
目的 :探讨细胞角蛋白 19(CYFRA2 1- 1)检测对非小细胞肺癌、良恶性胸腔积液 (以下简称胸液 )的诊断价值。方法 :采用免疫放射法 (IRMA)测定 6 2例非小细胞肺癌 (NSCLC)、38例结核性胸膜炎患者血清和胸水的CYFRA2 1- 1含量。结果 :CYFRA2 1- 1在两组胸水中的含量均明显高于血清含量 ;NSCLC组的胸水或血清CYFRA2 1- 1含量分别显著高于结核性胸膜炎组的血清或胸水含量。结论 :同时检测血清和胸水中CYFRA2 1- 1水平 ,可提高CYFRA2 1- 1对NSCLC的检出率 ,对NSCLC和良恶性胸液的诊断、鉴别诊断、疗效、预后均有较高的应用价值。
Objective: To investigate the diagnostic value of cytokeratin 19 (CYFRA2 1- 1) in the diagnosis of non-small cell lung cancer and benign and malignant pleural effusions (hereinafter referred to as pleural effusion). Methods: The levels of CYFRA2 1-1 in serum and pleural effusion of 62 patients with non-small cell lung cancer (NSCLC) and 38 patients with tuberculous pleurisy were determined by using immunoradiography (IRMA). Results: The content of CYFRA2 1- 1 in pleural effusion was significantly higher than that in serum. The content of pleural fluid or serum CYFRA2 1- 1 in NSCLC was significantly higher than that in tuberculous pleurisy. Conclusions: Simultaneous detection of CYFRA2 1 - 1 in serum and pleural effusion can improve the detection rate of CYFRA2 1- 1 in NSCLC, and has high value in diagnosis, differential diagnosis, curative effect and prognosis of NSCLC and benign and malignant pleural effusions.